Liraglutide preserves endothelial function in ophthalmic arteries of septic mice via prevention of oxidative stress.
Exp Eye Res · 2025
Last updated 2026-05-28In a study on mice with sepsis, those given the GLP-1 drug liraglutide showed better blood vessel function in their eyes compared to untreated septic mice. Specifically, the treated mice had preserved responses to acetylcholine, a chemical that tests blood vessel health, and lower signs of oxidative stress in their eye arteries. The untreated septic mice had worse blood vessel function and higher oxidative stress markers.
AI summary of the abstract below.
| Journal | Exp Eye Res, 2025 |
|---|---|
| Citations | 1 |
| Molecules | liraglutide |
Abstract
We hypothesized that the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide enhances endothelial functions in ophthalmic arteries of mice with polymicrobial sepsis. The study involved three groups of mice. Two groups underwent cecal ligation and puncture (CLP) to induce polymicrobial sepsis, with one of these groups receiving liraglutide treatment. The third group underwent sham surgery as a control. 24 h after the CLP procedure, the mice were euthanized, and ophthalmic arteries were isolated either for in vitro analysis of vascular function using videomicroscopy or for quantification of reactive oxygen species and redox genes or enzymes by PCR or immunohistochemistry. Vasoconstriction responses to the α-adrenoceptor agonist phenylephrine and vasodilation responses to sodium nitroprusside, an endothelium-independent vasodilator, were similar across all three groups. However, responses to acetylcholine, an endothelium-dependent vasodilator, were significantly impaired in ophthalmic arteries of septic mice. Notably, acetylcholine responses were preserved in septic mice treated with liraglutide. Additionally, dihydroethidium, and NOX2 antibody staining revealed a significant increase in markers for oxidative stress in the ophthalmic arteries of endotoxaemic mice, but not in those treated with liraglutide. In conclusion, activation of the GLP-1 receptor by liraglutide restrains endothelial dysfunction, reduces oxidative stress, and inhibits NOX2 overexpression in the ophthalmic arteries of endotoxaemic mice. These data suggest that GLP-1 receptor activation may provide a promising therapeutic strategy for treating ocular diseases characterized by oxidative stress and endothelial dysfunction.
Verbatim abstract via PubMed 40744307 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.